Delving into the Latest Updates on Abbott Japan LLC with Synapse

Evaluation of the utility of Abbott RealTime CMV in monitoring CMV infection of advanced cell-mediated immune deficiency patients by HIV infection - Abbott RealTime CMV Domestic Clinical Performance Trial

开始日期2017-11-21

申办/合作机构

Abbott Japan LLC

JPRN-UMIN000036827

/ CompletedN/A

Evaluation of the utility of Abbott RealTime CMV in monitoring CMV infection of patients after hematopoietic stem cell transplantation - Abbott RealTime CMV Domestic Clinical Performance Trial

开始日期2017-11-07

申办/合作机构

Abbott Japan LLC

JPRN-UMIN000036828

/ CompletedN/A

Evaluation of the utility of Abbott RealTime CMV in monitoring CMV infection of patients after kidney transplantation - Abbott RealTime CMV Domestic Clinical Performance Trial

开始日期2017-09-27

申办/合作机构

Abbott Japan LLC

100 项与 Abbott Japan LLC 相关的临床结果

登录后查看更多信息

0 项与 Abbott Japan LLC 相关的专利（医药）

登录后查看更多信息

21

项与 Abbott Japan LLC 相关的文献（医药）

2024-02-19·Journal of the Endocrine Society

Determination of Capillary Blood TSH and Free Thyroxine Levels Using Digital Immunoassay

Article

作者: Yoshimura, Toru ; Takeuchi, Miki ; Ito, Koichi ; Utsunomiya, Sosuke ; Arai, Yoshiyuki ; Noh, Jaeduk Yoshimura ; Miyazaki, Naoko ; Suzuki, Nami ; Tanaka, Katsumasa ; Sugino, Kiminori

AbstractBackgroundThe remote performance of thyroid function blood tests is complicated because it requires blood collection.ObjectiveTo compare TSH and free thyroxine (FT4) levels between capillary and venous blood and assess the adequacy of measuring each value in capillary blood.MethodsThis prospective intervention study was conducted at Ito Hospital and was based on the clinical research method. The participants were 5 healthy female volunteers and 50 patients (41 females and 9 males) between the ages of 23 and 81 years. To measure TSH and FT4 levels in capillary and venous blood, a digital immunoassay (d-IA) method capable of measuring trace samples was used. Chemiluminescence measurements were used as controls. Values obtained for each assay system were compared using Spearman's correlation analysis. Capillary blood was collected using an autologous device (TAP II; not approved in Japan).ResultsCapillary plasma volume obtained using TAP II was 125 µL or more in 26 cases, 25 µL to 124 µL in 24 cases, and less than 25 µL in 5 cases. Strong correlations were noted in the TSH and FT4 levels between capillary and venous blood, with correlation coefficients of rs = 0.99 and rs = 0.97, respectively.ConclusionCapillary TSH and FT4 levels strongly correlate with venous blood values. Trace samples can be used in high-precision d-IA methods. These results may promote telemedicine in assessing thyroid function.

2023-04-01·Vaccine: X

Serological response to a third dose of SARS-CoV-2 vaccine according to previous infection history.

Article

作者: Sasaki, Daisuke ; Sawai, Toyomitsu ; Mukae, Hiroshi ; Mitsumoto-Kaseida, Fujiko ; Ishihara, Kaori ; Onizuka, Masanari ; Yanagihara, Katsunori ; Murakami, Satoshi ; Kosai, Kosuke ; Hasegawa, Hiroo ; Furumoto, Akitsugu ; Usui, Tetsuya ; Makimoto, Noriaki ; Sakamoto, Kei ; Yoshimine, Hiroyuki ; Ota, Kenji ; Takazono, Takahiro ; Kohno, Shigeru ; Izumikawa, Koichi ; Asoh, Norichika

The IgG antibody titer against SARS-CoV-2 receptor binding protein (RBD) after mRNA vaccine were compared between those with and without previous infection (PI) for up to 48 weeks. Though sustained higher IgG-RBD were observed in the PI group after two doses of vaccines, both groups benefited from the booster shots of the third vaccine. This data supports the necessity of the booster shots to those with PI.

2023-01-01·Electrophoresis Letters

A novel diagnostic and predictive biomarker for the development of liver cancer and extrahepatic metastasis using the serum laminin γ2 monomer

作者: Kaneko, Ryo ; Funahashi, Nobuaki ; Yoshimura, Toru ; Koshikawa, Naohiko ; Yamashita, Taro

100 项与 Abbott Japan LLC 相关的药物交易

登录后查看更多信息

100 项与 Abbott Japan LLC 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2025年04月04日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

其他

3

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

GI-448 ( 50S subunit )	细胞内鸟分枝杆菌感染更多	终止
FY-609 ( H1 receptor )	过敏性鼻炎更多	终止
Olamufloxacin mesilate ( Bacterial DNA gyrase x Topoisomerase IV )	细菌感染更多	终止